Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193297
Status:
COMPLETED
Last Update Posted:
2011-05-03
First Post:
2005-09-12
Brief Title:
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the feasibility and toxicity of the combination of paclitaxel carboplatin and topotecan in patients with previously untreated stage III or IV epithelial ovarian carcinoma or primary peritoneal carcinoma We will also make a preliminary evaluation of the efficacy of this three drug regimen in the initial treatment of these patients
Detailed Description:
Upon determination of eligibility all patients will be receive
Paclitaxel Carboplatin Topotecan
a maximum of six courses of chemotherapy will be given at 21 day intervals
Paclitaxel Carboplatin Topotecan
a maximum of six courses of chemotherapy will be given at 21 day intervals
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 104864-644 | None | None | None |